¹ Microfluidics-Enabled Digital Isothermal Cas13a Assay

- 2 Frank X. Liu^{1,+}, Johnson Q. Cui^{1,+}, Hojeong Park^{2,3,+}, Ka Wai Chan⁴, Tyler Leung⁴, Ben Zhong Tang^{2,3,5,}
- 3 ^{*}, Shuhuai Yao^{1,2,*}
- 4 ¹ Department of Mechanical and Aerospace Engineering, The Hong Kong University of Science and
- 5 Technology, Clear Water Bay, Kowloon, Hong Kong
- 6 ² Department of Chemical and Biological Engineering, The Hong Kong University of Science and
- 7 Technology, Clear Water Bay, Kowloon, Hong Kong
- 8 ³ Department of Chemistry, Hong Kong Branch of Chinese National Engineering Research Center for
- 9 Tissue Restoration and Reconstruction, The Hong Kong University of Science and Technology, Clear
- 10 Water Bay, Kowloon, Hong Kong
- ⁴ DiagCor Life Science Limited, Kowloon Bay, Kowloon, Hong Kong
- ⁵ Shenzhen Institute of Molecular Aggregate Science and Engineering, School of Science and
- 13 Engineering, The Chinese University of Hong Kong, Shenzhen, 2001 Longxiang Boulevard, Longgang
- 14 District, Shenzhen City, Guangdong 518172, China
- 15 *†* indicates these authors contributed equally.
- 16 * corrensponding emails. tangbenz@ust.hk, meshyao@ust.hk
- 17
- 18
- 19
- 20

21 Abstract

22 The isothermal molecular diagnosis with CRISPR has attracted particular interest for the sensitive, specific detection of nucleic acids. However, most of the assays with Cas enzymes were performed 23 24 in bulk assays using multistep approaches and hard to realize quantitative detection. Herein, we 25 report Microfluidics-Enabled Digital Isothermal Cas13a Assay (MEDICA), a digital format of 26 SHERLOCK with enhanced robustness and sensitivity. We first address the macromolecular 27 crowding problems when combining the recombinase polymerase amplification (RPA) and 28 Cas13a detection into a one-pot SHERLOCK assay. After the assay optimization, the enhanced 29 one-pot SHERLOCK (E-SHERLOCK) achieves high robustness and 200-fold increased sensitivity. Leveraging droplet microfluidics, we streamline the E-SHERLOCK to eliminate 30 31 undesired input targets caused by pre-amplification before partition, enabling background-free absolute quantification. From the real-time monitoring, MEDICA enables qualitative detection 32 33 within 10 min and absolute quantification within 25 min. For the proof of concept, we applied MEDICA to quantify HPV 16 and 18 viral loads in 44 clinical samples, indicating perfect 34 35 accordance with qPCR results. MEDICA highlights the CRISPR-based isothermal assays are 36 promising for the next generation of point-of-care diagnostics.

37

38 Introduction

Rapid, robust, and inexpensive diagnostics are crucial in defense against the spread of viral
infections such as SARS-CoV, MERS-CoV, Ebola, Zika, avian, and swine influenza. The COVID
-19 pandemic highlights the unprecedented demand for rapid and sensitive nucleic acid detection
assays, which play a pivotal role in routine diagnosis, mechanistic and transmission studies,
vaccine development, and therapeutics for COVID-19¹. Quantitative polymerase chain reaction

(qPCR) has long been regarded as a gold standard for viral infection diagnosis². However, as a
centralized laboratory-based testing paradigm for viral diagnostics, PCR assays depend on
specifically designed TaqMan probes as well as precise thermal cycling, limiting their
deployability for community tests.

Recently, clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-48 49 associated (CRISPR-Cas) endonucleases are leveraged for nucleic acid detection through unique collateral trans-cleavage³⁻¹⁰. Programmable crRNA-guided CRISPR Cas12 and Cas13 can 50 specifically recognize the target sequence to promote trans cleavage of surrounded single-stranded 51 52 reporters^{11, 12}. Combined with a separate step of isothermal recombinase polymerase amplification 53 (RPA) preamplification, Cas13a based SHERLOCK (Specific High-sensitivity Enzymatic Reporter unlocking) and Cas12a based DETECTR (DNA endonuclease-targeted CRISPR trans 54 55 reporter) achieved attomolar sensitivity and single nucleotide polymorphism (SNP) identification ability^{13, 14}. Due to the strong collateral activity Cas13a^{8, 15, 16}, the SHERLOCK assay demonstrated 56 single-molecule detection ability when performing using a multistep process. However, the 57 multistep schemes not only increase the risk of contamination and human errors but also impose 58 difficulties and sample loss for the quantification of the target molecules. Even though 59 60 SHERLOCK can perform at a one-pot scheme, the macromolecular crowding agent issue and enzymatic incompatibility between RPA and CRISPR reactions result in less robust and sensitive 61 results compared to two-step reactions¹⁷. In addition, the one-pot reaction relies on the use of 62 63 standard curves and endogenous controls to obtain relative quantification, which has been shown to have significant variations^{18, 19}. In contrast to the standard curve calibration approach, absolute 64 quantification with improved precision and accuracy has been achieved by digital PCR²⁰ and 65 digital loop-mediated isothermal amplification (LAMP)²¹. In digital quantification, the assay 66

67 mixture is partitioned into a sufficient number of individual reactions so that either zero or one of 68 the target nucleic acid molecules is being amplified in each partition, and the assay result is 69 evaluated based on a simple positive-negative counting of the individual partitions based on the 70 end-point fluorescence measurement¹⁹. Yet, as far as we know, there is no digital SHERLOCK 71 assay available.

72 Different from PCR or LAMP that needs to be triggered by elevating the temperature, the 73 isothermal RPA and some of the CRISPR type V and VI endonucleases can react at room temperature²²⁻²⁴ so that the reaction would start to amplify the targets before the sample 74 75 partitioning into the nano-wells (e.g., QuantStudio 3D digital chips) or droplets using a simple flow-focusing system, which inevitably causes undesired overestimation due to pre-amplification 76 77 ²⁴⁻²⁶. To minimize the premature target amplification, one remedy is to prepare the reaction mixture on ice and quickly load it for partition²⁷. Hence, unlike hot-start digital PCR and LAMP, 78 79 the implementation of digital quantification of the near ambient temperature SHERLOCK needs a novel system for sample partitioning. Droplet microfluidics offers versatile yet controllable 80 81 handling of samples and reagents in forming droplets, and thus can effectively avoid premature 82 amplification before partitioning into droplets as well as facilitate combined amplification and trans-cleavage detection reactions in individual droplets. 83

In this work, we report Microfluidics-Enabled Digital Isothermal Cas13a Assay (MEDICA), the digital format of enhanced one-pot SHERLOCK (E-SHERLOCK). Digital quantification relies on a high signal-to-background ratio to convert the fluorescent signals of individual droplets to one or zero readouts, thus signal robustness and reproducibility are of great importance for digital quantification. However, when we conducted the one-pot SHERLOCK assay, the poor sensitivity and robustness of the reaction raised great concern. We identified the optimal reaction condition

90 enzymatic incompatibility and addressed the macromolecular crowding agent issue of the all-inone SHERLOCK assay, allowing robust detection at a single copy per microliter. We further 91 applied E-SHERLOCK assay into droplet microfluidics for digital quantification. Leveraging the 92 93 microfluidic design, MEDICA uses droplet compartmentation technology that effectively prevents 94 premixing by separation of the magnesium initiator from the target-included master mix, which 95 allows MEDICA to eliminate undesired premature amplification. Moreover, MEDICA showed an excellent signal-to-background ratio upon coordination of the reporter concentration with the 96 collateral reporting, enabling near background-free absolute quantification. Benefit from the 97 98 concentrated reaction within a picolitre droplet and the enhanced molecule mobility, MEDICA achieved qualitative detection within 10 min and quantitative detection within 25 min. Lastly, we 99 applied MEDICA to detect both HPV 16 and HPV 18 for clinical validation. MEDICA 100 101 successfully identified and quantified all viral HPV 16 and HPV 18 in clinical specimens, demonstrating excellent performance in line with qPCR results. 102

103

104 **Results**

105 Overview of MEDICA for viral HPV Detection.

We established the workflow of MEDICA and demonstrated its application for the detection of viral Human Papillomavirus (HPV) 16 and 18. HPV is critical for identifying the risk of HPVrelated cancers such as cervical cancer. Among all HPV types, HPV 16 and HPV 18 are accounted for the most precancerous lesions²⁸. We designed two MEDICA sequences that include two sets of forward primers with overhanging T7 promoter, Cas13a crRNAs to recognize both HPV 16 and HPV 18 for specific and sensitive tests (Figure 1a). RPA is a magnesium acetate (MgOAc) initiation nucleic acid amplification near ambient temperature compared to hot start LAMP and

PCR^{29, 30}. Since RPA starts as soon as MgOAc is added even at room temperature^{31, 32}, the 113 premature RPA amplification caused by directly mixing MgOAc with the master mix before 114 sample loading or partitioning would result in overestimated target input. To tackle this issue, we 115 116 separate MgOAc and the target-included master mix before loading them into the droplet generator. Adopting a flow-flowing configuration with two sample inlets (Figure 1b), MgOAc and the target-117 118 included master mix are loaded separately into the device and co-encapsulated into microdroplets in fluorinated oil 7500 with 2.5% EA surfactant. Thus, RPA is only triggered by MgOAc after 119 droplet formation. The droplet generator enables high throughput generation of monodisperse 120 droplets of $\sim 30 \,\mu\text{m}$ in diameter at one kHz, which is more rapid and efficient than nano-well-based 121 digital loading^{33, 34}. By droplet partitioning, a single target DNA is confined in a small volume in 122 123 which the signal can be amplified and concentrated for detection. The generated emulsions are 124 then incubated at 37 °C before fluorescence imaging. This one-pot reaction contains extensible RPA amplification with T7 overhangs, RNA activator transcription by T7 RNA polymerase, and 125 126 CRISPR Cas13a ternary collateral detection (Figure 1c). During the one-pot enzymatic activity, 127 the unique adaptable reporting feature of Cas13a nuclease barely digests DNAs, leading to extremely high sensitivity. Our droplet-based MEDICA allows absolute counting of the target 128 DNA molecules to achieve unprecedented accuracy. 129



130

131 Figure 1. Overview of targeting sequences and MEDICA process. a, The genome map of both HPV 16 and HPV 18. The selected CRISPR detection regions of HPV 16 L1 and HPV 18 E1 are 132 133 annotated with red lines in the genome, which covers the forward RPA primer with extended T7 region overhang, targeted protospacer, and reverse primer. The targeted HPV 16 region has 137 134 bp (from 5743 bp to 5880 bp) while the HPV 18 detection region has 118 bp (from 1045 bp to 135 1163 bp). Spacer represents the crRNA spacer. b, The workflow of the digital quantification 136 process. A master mix with the extracted sample and magnesium initiator (MgOAc) are prepared 137 separately and flow in the droplet generator as two aqueous phases. MgOAc triggers the reaction 138

as soon as droplets are formed. After incubation at 37 °C for 30 min RPA and Cas13a reactions, the droplets are imaged by fluorescence microscopy and counted for quantification of the target molecule concentration. **c**, The all-in-one molecular reaction inside a droplet. With the initiation of MgOAc, RPA enzymes amplify the target sequence to generate numerous amplicons with a sequence extension of the T7 promoter region. Then T7 RNA polymerase transcripts target protospacer into RNAs to activate Cas13a for trans-cleavage reporting.

145

146 Optimization of the one-pot SHERLOCK assay

Combining RPA with Cas13a in a one-pot reaction with high sensitivity and reproducibility is 147 critical to ensure the accuracy and robustness of the quantification results. Therefore, we started 148 with assay development which is a prerequisite to digital quantification. However, when we 149 conducted the one-pot assay directly combining the reagents used in the two-step SHERLOCK ³⁵. 150 we found the results had dramatical fluctuation and thus compromised sensitivity compared to the 151 152 two-step approaches (Figure 1a, supplementary S2). The digital quantification relies on the statistical calculation of the positive droplets that contain fluorescence signal higher than the 153 threshold ¹⁹. The irreproducibility of the reactions in droplets would result in massive rain droplets 154 155 whose signals are between the positive and negative controls, leading to a high error to absolute quantification³⁶. Therefore, in circumventing these challenges, a compatible and robust one-pot 156 SHERLOCK assay needs to be established in order to minimize the uncertainty in counting the 157 positive droplets. These signal fluctuations and uncertainty are likely caused by the reaction 158 component incompatibility and viscous condition^{17, 37}. 159

Subsequently, we performed multiple rounds of assay optimization to identify the key factors ofthis reaction. First, we investigated the components of the reaction buffer including pHs, salts, and

162 other additives. We found the 60 mM pH 7.5 Tris-HCl buffer with 80 mM KCl yielded the highest 163 signal, much better than the HEPES buffer used for SHERLOCK detection (Figure 2b and supplementary S3a). The commonly used RPA mixture is highly viscous due to the presence of a 164 165 high molecular crowding agent to enhance the catalytic activity and increase specificity as well as sensitivity²⁹. Macromolecular crowding increases the binding of polymerase to DNA and reduces 166 the thermodynamic activity, resulting in localized reagent depletion³⁸. Thus, additional 167 components in low concentration are difficult to be distributed homogeneously. We then explored 168 the influence caused by PEG 8000. The reaction was activated with the presence of PEG 8000 169 (Figure 2c), however, as the concentration of PEG 8000 increased over 5 %, the fluorescence 170 171 signal of the one-pot reaction fluctuated dramatically. This result indicated that the collateral activity was affected by the viscosity of the reagent as the biomolecules of the Cas13a system are 172 173 restricted in RNA activator transcription, Cas13a ternary trans reporting. Compared to the hot-start PCR assisted by PEG, the molecule diffusion is enhanced with the high temperature where the 174 non-concentration components are distributed homogenously. Hence, we chose 2.5 % PEG 8000 175 176 to minimize the signal fluctuation caused by nonhomogeneous molecule distribution while maintaining robust detection performance. Moreover, we added 0.05 % tween 20, a surfactant 177 commonly used in droplet microfluidics³⁹, to reduce the viscosity even further (Supplementary 178 S3c). We compared the viscosity of the final enhanced reaction buffer (e-reaction) with other PEG-179 based reaction buffers (Figure 2d). The optimal one-pot reaction buffer is less viscous than most 180 181 of other PEG-based reaction buffers. These improvements decrease the viscosity of the reaction 182 buffer, in another word, the molecule diffusion ability was increased at a lower temperature. To further enhance the detection ability, we optimized the primer concentration for this one-pot 183 184 reaction (Supplementary S4a). 120 nM and 360 nM primers resulted in a strong fluorescence signal

and 360 nM primer performed better at 10 cp/µL concentration (Supplementary S4b). Besides, we
optimized all the other related components including crRNA to Cas13a ratio, T7 RNA
(Supplementary S4c and d).

188 After these major optimizations, we compared our E-SHERLOCK with the standard two-step SHERLOCK to test the sensitivity and specificity. The optimized assay indicated consistent 189 190 detection ability (Figure 2e). Then we conducted the specificity of this assay to detect the HPV16 L1 gene, HPV18 E1 gene. Four synthetic plasmids containing HPV 16 L1 gene, HPV 18 E1 gene, 191 SAR-CoV-2 ORF gene, and SAR-CoV-2 N gene, were applied. We spiked the targeted HPV 16 192 193 into the unrelated samples to compare the performance inside the complicated matrix (Figure 2f). E-SHERLOCK demonstrated high specificity with spiked samples. Lastly, we evaluated the 194 sensitivity of the E-SHERLOCK. It achieved 1 cp/µL in a bulk solution (Figure 2g and 195 196 Supplementary S7). The theoretical limit of detection (LOD) is 0.06 cp/uL (Supplementary S6). Compared to the initial one-pot assay, the optimized assay has improved both robustness and 197 sensitivity of the assay (Supplementary S5). The optimized one-pot SHERLOCK increased a 198 199 maximum of 76-fold of stability, and 200 times of sensitivity (Supplementary S5 and S6). We 200 sought to verify the clinical performance of our enhanced one-pot SHERLOCK by conducting a clinical validation to detect both HPV 16 and HPV 18 (Figure 2h). Among other sexually 201 transmitted diseases (STD) including Neisseria gonorrhoeae (NG) and Chlamydia trachomatis 202 (CT), the one-pot SHERLOCK identified all clinical samples within 30 min, which is in 100% 203 204 agreement with qPCR results (Table 1).



Figure 2. Construction of E-SHERLOCK. a, The fluorescence signals show a wide range of 206 variations using the initial one-pot SHERLOCK in bulk for detection of synthetic HPV 16 plasmid 207 from 1000 cp/ μ L to 5 cp/ μ L. **b**, The pH and salt optimization for one-pot SHERLOCK. Tris-HCl 208 of pH 6.8, 7.5, 8, and different concentrations was compared. Sodium chloride (NaCl), amino 209 210 sulfate ((NH₄)₂SO₄), potassium chloride (KCl), and potassium acetate (CH₃COOK) of different concentrations were compared. c, PEG 8000 of 0, 2.5, 5, and 7.5% was compared. d, The viscosity 211 comparison of different reaction conditions using different concentrations of PEG8000, the e-212 reaction buffer represents the optimal reaction buffer. e, The comparison of two-step and the 213

214 optimized one-pot SHERLOCK after 1 h using HVP 16 plasmid. f, The specificity of one-step 215 SHERLOCK with or without spiked plasmid targets. ORF and N indicate the SARS-CoV-2 ORF gene and N gene, respectively. g, The real-time fluorescence of the optimized one-pot assay for 216 217 detection of a serial dilution of HPV 16 plasmid from 1000 cp/ μ L to 1 cp/ μ L. h, The clinical validation of E-SHERLOCK. HPV 16, HPV 18, NG, and CT samples were tested to verify the 218 one-pot SHERLOCK performance. The green color group represents the HPV 16 detection while 219 220 the blue group shows the HPV 18 diagnosis. For **a** and **g**, the filled area represents the error bar (s.d.) of each group. For **c-f**, the center is the mean of 3 technical replicates, while the error bar 221 indicates the s.d. For **d**, the two-tailed student's t-test; ****P<0.0001. For **b** and **c**, the 222 concentration of plasmid HPV 16 is 10 cp/uL. The NTC represents the non-template control. 223

224

225 Real-time and end-point quantification with MEDICA

The E-SHERLOCK achieved high sensitivity and robust detection ability. However, the reaction time (30-40 min) compared to the typical RPA reaction (20-30 min) is over-extended. Droplet digital methods can increase the localized reaction concentration thus shortening the reaction time. Additionally, the droplet digital technique offers more precise quantification results compared to real-time quantitative detection. Therefore, we applied droplet microfluidics to covert our optimal assay into digital format.

The droplet digital assay contains three steps, droplet partition, droplet incubation, and digital visualization. To realize the MgOAc and target-included master mix separation and mix, we separated the two phases and let them flow into a two-inlet droplet generator (Supplementary S8 a). Due to the different viscosity of the two phases, the pressures applied were adjusted to achieve an equal volume flow rate for mixing in droplets. The mixture of MgOAc and Target-included

master mix was encapsulated into picoliter-sized water in oil droplets (~30 µm) (Supplementary
S9). The resulting monodisperse emulsion droplets were incubated at 37 °C. After incubation,
droplets were imaged by fluorescence microscopy and analyzed for the target concentration
quantification.

We firstly evaluated the total reaction time of MEDICA. A customized stage was developed to 241 242 capture the images of *in-situ* MEDICA (Supplementary S11). In the real-time MEDICA, we were able to detect significant fluorescence signals within 10 min when significant numbers of droplets 243 are present (Figure 3a). We found the positive droplet ratio increased dramatically in 10-15 min 244 245 and reached a plateau after 20 min (Figure 3b). In terms of the total fluorescence intensity, it 246 increased until 25 min when the signals in droplets became saturated and where the amplification time (Cq) is between 5 to 10 min (Figure 3c). This indicates that the real-time MEDICA only took 247 248 around 5-10 min for detection which is more rapid than the corresponding assay in bulk solution. 249 We postulated that this is because the RPA and CRISPR reactions are accelerated within a picoliter 250 confined compartment, and the signals generated are concentrated to facilitate the detection. The enhanced mobility of molecules in a less viscous fluid in droplets also contributes to the mixing 251 252 of the reagents and therefore shortens the overall reaction time. Similar results have been reported in which the reaction in droplets is accelerated $^{40, 41}$. 253

Subsequently, we calibrated MEDICA by end-point quantification using serially diluted samples of synthetic HPV 16 plasmid. The results are shown in figure 3d. The absence of the MgOAc group emitted even less fluorescence on average than the non-template control (NTC) group, which further indicates that the reaction was completely suspended without the sole magnesium co-factor. The total and positive droplets were counted using ImageJ and customized Matlab code (Supplementary S10). Figure 3e shows the fluorescence intensity from the NTC group, which was

260 below the threshold. The highest intensity of the recorded droplets from the NTC group is less 261 than 0.5 after normalization, while all the positive droplets were selected over 0.6. Thus, MEDICA enables near background-free digital quantification. By tailoring the reporter concentration, the 262 263 signal-to-background was steadily enhanced by increasing the reporting concentration (Supplementary S12), which can be attributed to the unique collateral cleavage of Cas13a. We 264 obtained a linear correlation between the theoretical concentration and the measured concentration 265 (Figure 3f). We were able to quantify as low as 6 copies in total 20 μ L volume. Therefore, 266 MEDICA demonstrated the single-molecule detection ability and high precision quantification 267 from 0.3 cp/ μ L to 1,000,000 cp/ μ L. We further tested the robustness of MEDICA to quantify HPV 268 18 E1, SARS-CoV-2 ORF, and N genes. We observed the equivalent linear correlation of all the 269 groups (Figure 3g), which further indicated the versatility of MEDICA. Finally, we tested the 270 271 specificity of MEDICA in multiple conditions with or without the spiked samples. Taking HPV 16 as the main viral target, MEDICA successfully differentiated all the targets with consistent 272 results (Figure 3h). 273





Figure 3. Real-time and end-point MEDICA. a, The fluorescence images of the real-time MEDICA (0-20 min) for quantification of 100,000 cp/uL HPV 16 plasmid. b, The percentage of positive droplet ratio along the reaction time. 10 min was the turnover point for qualitative

278	detection, and the ratio was saturated around 25 min. c, The average intensity of all droplets over
279	the reaction time. The highest fluorescence was yielded around 25 min. d, The fluorescence images
280	of the end-point MEDICA using a serial dilution of the sample ranging from 1×10^6 cp/µL to
281	NTC. The extra control group was 1×10^5 cp/µL with the absence of the MgOAc initiator. e , The
282	statistical analysis of the end-point results. f , The measured concentration is in excellent agreement
283	with the expected concentration. EXP1, EXP 2, and EXP 3 represent the three technical replicated
284	experiments. g, Quantification of the SARS-CoV-2 ORF gene, SARS-CoV-2 N gene, and HPV
285	18 N gene by MEDICA. h, Specificity test of MEDICA to target HPV 16 with or without spiked
286	into ORF and N gene groups. The concentration was 1×10^5 cp/µL. Error bars represent the 95 %

287 confidence interval.

288 Clinical validation of MEDICA



289

Figure 4. Clinical validation of MEDICA. a, Overview of MEDICA for viral HPV detection
using clinical swab samples. b, Comparison of MEDICA quantification results with qPCR results
for detection of HPV 16. MEDICA identified all clinical samples with the same tend of qPCR. c,
Comparison between MEDICA quantification results and qPCR quantification of HPV 18. d

Correlation between the HPV 16 concentrations measured by MEDICA and the real-time qPCR
C_t values. e Correlation between the HPV 18 concentrations measured by MEDICA and the realtime qPCR C_t values.

297

Finally, we demonstrated the feasibility of MEDICA to detect clinical viral HPV 16 and 18 298 299 samples. We evaluated the absolute quantification results of MEDICA with qPCR. After obtaining the standard curves of qPCR for HPV 16 and HPV 18, we compared the performance of MEDICA 300 and qPCR. Both qPCR and MEDICA differentiated all the viral clinical specimens of HPV 16 and 301 302 HPV 18 (Figure 4b and 4c). The concentration variation of the two methods indicates the same tendency. Since the C_t (threshold cycle) values straightforwardly represent the raw target 303 concentration, we correlated the correlations of measured concentration from MEDICA with the 304 C_t values of qPCR to verify the consistency of their results. The overall correlations of the 305 measured Ct values and the quantified concentrations from MEDICA (Figures 4d and e) follow 306 307 the expected trend. However, at the lowest concentration of HPV 18, the difference between these two methods tended to diverge. The absolution quantification tended to decrease slower than the 308 real-time method. We believe these differences can be explained by two reasons. Firstly, when 309 310 the input copies are limited, the qPCR quantification is likely to have significant differences in quantification results compared to the digital method¹⁹. Secondly, the concentration of the clinical 311 samples may change after several rounds of freeze-thaw, resulting in this difference. The clinical 312 validation further confirms that MEDICA offers rapid, accurate, and direct quantification of 313 nucleic acids from clinical specimens. 314

315

316 **Discussion**

317 Identification and quantification of trace amounts of nucleic acids are of great importance for public health and molecular biology study. Herein, we developed droplet digital quantification 318 319 with a one-assay of RPA and Cas13a for viral nucleic acids (MEDICA). This microfluidic assay 320 allows rapid and sensitive nucleic acid detection within 10 min and 25 min for absolute 321 quantification. The enhanced one-pot reaches single copy per microliter detection around 35 min. 322 When combined with droplet microfluidics, the droplet digital method confines the single-323 molecule within a single emulsion around picoliter volume to increase the localized concentration, 324 shortening the reaction time. With simple ancillary equipment, MEDICA demonstrated a promising isothermal nucleic acid detection with Cas13a against rival thermal cycling PCR. The 325 inborn collateral trans-cleavage of Cas13a is harnessed for signal amplification with the increase 326 of molecule mobility, resulting in a uniform fluorescence readout. 327

328 Compared to previously reported one-pot hot-start CRISPR assays, our enhanced one-pot reaction 329 required a lower reaction temperature, spotlighting the promising point of care diagnostics with simple requirements. Recently, the one-pot RPA with Cas12a and Cas13a was reported to attain 330 high sensitivity through component optimization^{4, 7}. However, these assays might be unable to 331 achieve digital quantification due to irreproducible results by the influence of macromolecular 332 crowding agents. This issue is originated from the RPA reaction, where the high molecular weight 333 334 PEG hinders the movements of other molecules such as T7 polymerase, Cas13a nuclease, crRNA, and reporters, and thus affecting the trans-cleavage of reporters before or after CRISPR ternary 335 336 activation. In PCR system, the high concentration of macromolecular crowding agent PEG is widely applied to enhance the sensitivity and specificity⁴². However, the high reaction temperature 337 compared to the SHERLOCK test could increase the thermal diffusion of biomolecules, alleviating 338

the inhomogeneous distribution. Therefore, at the near-ambient temperature reaction, the high concentration of PEG would inevitably affect the molecule diffusion. We reduced the concentration of the viscous PEG to define the trade-off between the RPA reaction and Cas13a readout for increased reproducibility. These improvements lead to the ultimate enhancement of trans-reporting of Cas13a. Thus, the optimized one-pot RPA and Cas13a reaction attain fast RPA reaction and powerful trans-reporting. Our optimal assay exhibits robust and reproducible detection ability at a single copy per microliter.

Digital assays near ambient temperature could easily induce inaccuracy during manual operations 346 347 of sample preparation and partitioning. Hence, compartmentation technologies such as nano-wells and simple flow-focusing devices may lead to the overestimated detection results. We arranged 348 the resuspension of the sole MgOAc initiator and master mix, enabling the reaction to be triggered 349 350 after monodisperse emulsion. The microfluidic approach improves the accuracy and robustness of digital quantification. With the collateral enhanced one-pot assay, MEDICA achieved a uniform 351 high signal-to-background ratio, avoiding rain droplets in discrimination of the positive and 352 negative droplets. In addition, the picoliter scale reaction in droplets enhances the molecular 353 354 mixing and collision in confined space, greatly promoting the efficiency of this assay. Because of 355 its rapidity, sensitivity, specificity, and simple ancillary equipment, we expect that MEDICA holds 356 great potential for system integration and miniaturization for point-of-care diagnostics.

357

358 Materials and Methods

359 Chemicals

360 Detailed information about reagents, including the commercial vendors and stock concentrations,

all chemicals and sequences related to this work are listed in supplementary table 4 and table 5.

362 LwaCas13a protein extraction

LwaCas13a protein extraction was performed by following a previously published protocol with 363 minor modifications¹⁷. E. coli Rosetta 2(DE3) pLysS transformed with the pC013 364 365 TwinStrep-SUMO-huLwaCas13a expression (Addgene plasmid #90097) and cells were cultured at 37 °C in 15 mL of Luria-Bertani (LB) medium containing 100 µg/mL ampicillin. Large-scale 366 growth cultures were initiated by the addition of 5 mL of the starter cultures into 1 L of LB medium 367 containing 100 μ g/mL ampicillin and allowed to grow at 37 °C until the OD₆₀₀ reached the range 368 of 0.4 to 0.6. The cultures were transferred to 4 °C for 30 min to allow them to cool before the 369 protein induction. The cultures were grown in a pre-chilled 16 °C biological shaker for 18 h with 370 371 0.1 mM IPTG. Cells were harvested, resuspended in 4X (wt/vol) supplemented lysis buffer composed of 20 mM Tris-HCl (pH 8.0), 0.5 M NaCl, 1 mM DTT, 2 cOmplete Ultra EDTA-free 372 373 tablets, 100 mg of lysozyme, and 1 uL of benzonase to 60 mL of lysis buffer, and ruptured on ice by sonication (Q500, QSONICA). The lysate was centrifuged for 60 min at 10,000 rpm. at 4 °C. 374 The supernatant was collected into a 50 mL falcon tube, and 0.5 mL of Strep-Tactin superflow 375 376 Plus resin was added to the supernatant. The recombinant protein was bound to the resin for 3 h by gentle shaking at 4 °C. The resin-sample suspension was poured into 50-mL Bio-Rad glass 377 Econo-Column equilibrated with cold lysis buffer. After flow-through was removed, the column 378 379 was washed with 50 mL cold lysis buffer three times. 5 mL of SUMO protease cleavage solution composed of 5 mL of lysis buffer, 50 µL of SUMO protease, and 7.5 µL of NP-40, was added to 380 the column, followed by and gentle shaking at 4 °C for 18 h. The cleavage solution was collected, 381 382 and the column was washed three times with 5 mL of lysis buffer. The collected cleavage solution

was dialyzed in 2 L of 1X PBS in a cellulose membrane dialysis tube for 18 h. The presence of
recombinant was identified using SDS-PAGE gel analysis (Supplementary S1). Amicon Ultra-0.5
mL centrifugal filter was used to concentrate protein and re-diluted in protein storage buffer, which
allows the protein for storage at -80 °C for up to 6 months.

387 Clinical extraction and qPCR validation

Clinical swab samples were provided by DiagCor Bioscience from clinical doctors in compliance
with ethical and safety approval by Human Research Ethics Committee and Health, Safety and
Environment Office of HKUST.

We used QIAamp DNA Mini Kit (Qiagen) to extract the viral RNAs according to the manufacturer's protocol. The raw urine sample is 10 mL each. After extraction, samples were collected with a 1.5 mL tube and stored at -20 °C before use.

The qPCR was performed with a master mix of 20 μ L including 10 μ L of 2X Taq polymerase, 0.5 µL of 10 uM forward and reverse primers each, 0.5 μ L of 10 μ M probes, 5.5 μ L of nuclease-free water, and 2 μ L of target sample from the extraction. After gentle mixing, the two-step PCR was conducted with 30 s pre-heating followed by 45 cycles of 5 s at 95 °C (denaturation) and 30 s at 60 °C (annealing and extension). All the qPCR experiments were conducted with a Roche Lightcycler 480 II (Roche) at HKUST BioCRF.

400 One-step and two steps SHERLOCK

The one-step SHERLOCK was conducted with a 20 μ L volume for each test. For experimental preparation, one lyophilized pellet was resuspended with 100 μ L of final master mix with 10 μ L of target and 5 μ L of MgOAc (280 mM) deprived. The master mix was firstly prepared including 59 μ L of rehydration buffer from the kit, 4 μ L of LwaCas13a (1 μ M), 4 μ L of rNTP mix (25 mM),

1 μ L of Rnase inhibitor Murine (40 U/ μ L), 4.8 μ L of each forward and reverse primers (10 μ M), and 1.25 μ L of Poly(U) reporter (10 μ M). After reconstitution with one lyophilized pellet with gentle mixing, this mixture was aliquoted into 5 groups (17 μ L). Then, 2 μ L of target sample and 1 μ L of MgAOc (280 mM) were pipetted into accordingly with quick mixing before incubation. The sample was incubated with a Roche Lightcycler 480 II (Roche) at 37 °C. The fluorescence was measured every minute for one hour.

The two-step SHERLOCK is divided into two aspects: First, the RPA pre-amplification was triggered by adding MgOAc from the kit instructed with TwistAmp® Basic at 37 °C for 20 min.
Second, 1 µL of the RPA product was added to 19 µL of Cas13a detection master mix consisting of 20 mM HEPES (pH 6.8), 9 mM MgCl₂, 1 mM rNTP mix, 40 nM LwaCas13a, 1 U/µL RNase inhibitor murine, 0.125 U/µL T7 RNA polymerase, and 125 nM poly(U) RNA reporters. The fluorescence from the Cas13a trans-cleavage detection was then measured every 30 s using a Roche Lightcycler 480 II at 37 °C for 30 min.

418 Buffer construction and optimization for enhanced one-pot assay

419 The optimization of components of RPA and Cas13a reaction started with an initial reaction including 1X buffer containing 50 mM Tris-HCl (pH 8.0), 60 mM NaCl, 5% PEG 8000, and 2 420 421 mM DTT. The initial master mix was created with 100 nM Cas13a, 1 mM rNTP mix, 10 U of RNase inhibitor Murine, 100 nM crRNA, 5U of T7 RNA polymerase, 125 nM PolyU reporters, 422 423 and 480 nM of each forward and reverse primers, and one lyophilized pellet from the basic RPA kit. In all experiments, the master mix without MgOAc was used to suspend the lyophilized pellet 424 (one pellet to 100 µL final reaction volume). After reconstitution, this master mix was aliquoted 425 426 accordingly, each group contains 17 μ L of reconstituted master mix. Then, 2 μ L of the synthetic

427 sample or viral specimen was pipetted into this master mix with thorough mixing. Finally, 1μL of
428 MgOAc (280 mM) from the kit was added to trigger this reaction.

Then optimization occurred iteratively with each reagent modification. We identified each 429 430 component to yield the best signal then kept the optimal reagent tested previously when conducted the next optimization. We evaluated the performance of Tris-HCl with different concentrations 431 432 (10, 20, 40, 60, 80, and 100 mM) as well as pH (6.8, 7.5, and 8.0). For the salt components, we 433 tested NH₄(SO₄)₂, NaCl, KCl, and CH₃COOK at different concentrations (20, 60, and 80 mM), respectively. Then, we optimized the PEG-8000 concentration (0, 2.5, 5, and 7.5%). For the 434 435 additives, we tested the Tween 20 (0, 0.05, 0.1, 0.2, and 0.5%) and DTT (0, 1, 4, 10, and 20 mM), respectively. After the buffer construction, we further optimized primer concentration (60, 120, 436 240, 360, and 480 nM), crRNA to Cas13a ratio (0, 0.5, 1, 2, 3, and 3.75), T7 polymerase (0, 0.1, 437 0.4, 0.8, and 2 U/ μ L) respectively. All the modulated reaction components are shown in figures 438 and associated figure captions. 439

440 **E-SHERLOCK in bulk**

The final one-pot assay contains 1X reaction buffer (60 mM Tris-HCl pH 7.5, 80 mM KCl, 2.5% PEG-8000, 0.05% Tween 20 and 1 mM DTT), 40 nM Cas13a, 1 mM rNTP mix, 10 U Rnase inhibitor Murine, 40 nM crRNA, 0.8 U/µL T7 RNA polymerase, 125 nM Poly (U) reporters, and 360 nM each forward and reverse primers, and the enzymes from the lyophilized pellet (one pellet to 100 µL final master mix including the target). Once the master mix is created, it is used to resuspend the lyophilized pellets. The final reaction volume is 20 µL containing 17 µL of aliquoted master mix, 2 µL of target sample, and 1µL MgOAc (as the last component to start this reaction).

We further evaluated the performance of the sensitivity, specificity, and comparison of this onepot reaction. All the experiments were conducted in real-time with the Roch Lightcycler 480 II with fluorescence measurement every minute at 37 °C for 1 h. For the specificity test, the spiked genes were firstly prepared at 1×10^5 cp/µL and mixed mutually before experiments.

452 Droplet microfluidic device design and fabrication

The microfluidic device consists of Y-shaped two inlets for MgOAc and target-included master mix respectively, and two symmetric oil channels (fluorinated oil 7500 with 2.5 % EA surfactant) to form a flow-focusing droplet generator. The thickness of this device is 35 μ m, and all the inlets are 40 μ m until the flow-focusing junction with tiny modification. The aqueous phase channel of the junction is 30 μ m while the oil channel is 25 μ m. The outlet channel is 100 μ m till the end.

The device was made of polydimethylsiloxane (PDMS, Sylgard 184 silicone elastomer, Dow 458 459 Corning) using a soft lithography process. First, photoresist SU8 (3025) provided by NFF was 460 deposited on a silicon wafer by spin coating. Then, the coated wafer was taken for micropatterning by employing photolithography (SUSS Mircotec MA6, Garching, Germany). Finally, the wafer 461 was baked and developed (SU-8 developer; MicroChem, Westborough, MA, USA), forming a 462 463 master for PDMS replica molding. To facilitate the molding of the PDMS device, Trichloro (1H, 1H, 2H, 2H-perfluorooctyl) silane 97% (Sigma-Aldrich, St. Louis, MO, USA) was used to coat 464 the surface in a desiccator. PDMS mixture was prepared by mixing PDMS and solvent at a weight 465 ratio of 10:1, which was poured on the silicon wafer. After baking at 80 °C for 1 hour, the PDMS 466 layer was peeled off from the silicon master and then cut into an individual section. The final 467 microfluidic chip was formed after bonding the PDMS to a glass substrate after oxygen plasma 468 treatment. The microchannels were rendered hydrophobic after being treated with Aquapel, which 469 470 is suitable for water-in-oil droplets formation. After binding, the microfluidic chip was firstly pre-

treated with aquapel (PPG Industries) to yield hydrophobicity and followed by fluorinated Novec
7100 (3M) washing for 30 s. The microfluidic chip was incubated at a hotplate at 80 °C before use.

473 **MEDICA quantification**

The experiment was conducted with a pressure box (Everflow) to control the three phases 474 (magnesium phase, master mix with target and oil phase). The total reaction volume is 20 µL 475 476 containing two phases with equal volume. the 10 µL of magnesium phase contains 1X reaction buffer, 28 mM MgOAc. 10 µL of the other phase includes 1X enhanced reaction buffer, 80 nM 477 Cas13a, 2mM rNTP, 16 U of Rnase inhibitor Murine, 80 nM crRNA, 1.6 U/µL T7 polymerase, 478 479 720 nM each forward and reverse primers, 1 μ M poly(U) reporters, and 2 μ L of 1X target sample. For end-point MEDICA, after 30 min incubation at 37 °C, droplets were pipetted into a 30 µm 480 481 thick microchamber for fluorescence imaging. For the real-time MEDICA, firstly a heating system 482 with a Peltier on microscopy was made with a PMMA frame. The temperature was calibrated to 483 37 °C. The sample was partitioned then collected on ice. Then, all the droplets were pipetted into 484 a silicon chamber (30 µm) on ice. The inlet and outlet were sealed with optical adhesive film (Thermo Fisher). The time (0) image was recorded without heating. Then, the heating source was 485 opened to record the fluorescence signal evolving with time. We used the synthetic SARS-CoV-2 486 ORF plasmid as an example to measure the real-time fluorescence change. The master mix was 487 prepared with 1×10^5 cp/µL target input, following the same protocol as MEDICA. The 488 489 amplification time (Cq) for classifying samples as positive or negative was set to approximately

490 10 % of the average steady state fluorescence signal.

491 The droplet imaging system includes a LED light source with a 488 nm filter and a Nikon492 microscope. All the information (number and fluorescence intensity) was calculated by ImageJ

493 (NIH). The detailed process of image analysis is listed in supplementary S10. According to the 494 Poisson law, the average number of target DNA per droplet λ was calculated through the 495 possibility of positive droplets ($p_{postive}$). Let *M* to be the total number of droplets and $V_{droplet}$ to 496 be the average droplet volume. The molar concentration of the target *n*, can be

497
$$\lambda = -\ln(1 - p_{postive}) \tag{1}$$

498
$$n = \frac{\lambda}{V_{droplet}}$$
(2)

499

500 Acknowledgments

We would like to thank HKUST NFF for microfluidic chip fabrication, and HKUST BioCRF for
the essential equipment supports. This work is supported by the University-Industry Collaboration
Programme (Grant No. UIM/362) under Innovation and Technology Fund of Hong Kong.

504

505 Author contributions

506 S.Y. and B.T. conceived and supervised the project. F.L., Q.C. and H.P designed the research. H.P 507 purified the proteins and performed the verification. F.L. developed the assay and clinical PCR 508 validation. F.L. and Q.C developed the microfluidic chip and conducted the droplet quantification 509 experiments. Q.C developed the method for droplet analysis. K.C and T.L collected and purified 510 all the clinical samples. F.L., Q.C., and H.P., analysed the data. F.L., Q.C., H.P., and S.Y. wrote 511 the manuscript. All authors edited the manuscript.

512

513 Competing interests

514 The authors declare no competing interests.

515

516 **References**

- 517 1. Wang, C., Horby, P. W., Hayden, F. G. & Gao, G. F. A novel coronavirus outbreak of global
- 518 health concern. *The lancet* **395**, 470-473 (2020).
- 519 2. Vogels, C. B. et al. Analytical sensitivity and efficiency comparisons of SARS-CoV-2 RT-
- 520 qPCR primer–probe sets. *Nature microbiology* **5**, 1299-1305 (2020).
- 3. Ackerman, C. M. *et al.* Massively multiplexed nucleic acid detection with Cas13. *Nature* 582,
 277-282 (2020).
- 4. Arizti-Sanz, J. et al. Streamlined inactivation, amplification, and Cas13-based detection of
- 524 SARS-CoV-2. *Nature communications* **11**, 1-9 (2020).
- 525 5. Barnes, K. G. *et al.* Deployable CRISPR-Cas13a diagnostic tools to detect and report Ebola
- and Lassa virus cases in real-time. *Nature communications* **11**, 1-10 (2020).
- 527 6. Broughton, J. P. *et al.* CRISPR–Cas12-based detection of SARS-CoV-2. *Nat. Biotechnol.* 38,
 528 870-874 (2020).
- 529 7. Ding, X. et al. Ultrasensitive and visual detection of SARS-CoV-2 using all-in-one dual
- 530 CRISPR-Cas12a assay. *Nature communications* **11**, 1-10 (2020).

- 531 8. Gootenberg, J. S. *et al.* Multiplexed and portable nucleic acid detection platform with Cas13,
- 532 Cas12a, and Csm6. *Science* **360**, 439-444 (2018).
- 533 9. Joung, J. et al. Detection of SARS-CoV-2 with SHERLOCK one-pot testing. N. Engl. J. Med.
- **383**, 1492-1494 (2020).
- 535 10. Patchsung, M. et al. Clinical validation of a Cas13-based assay for the detection of SARS-
- 536 CoV-2 RNA. *Nature Biomedical Engineering* **4**, 1140-1149 (2020).
- 537 11. Knott, G. J. & Doudna, J. A. CRISPR-Cas guides the future of genetic engineering. *Science*538 361, 866-869 (2018).
- 12. Chertow, D. S. Next-generation diagnostics with CRISPR. Science 360, 381-382 (2018).
- 540 13. Gootenberg, J. S. *et al.* Nucleic acid detection with CRISPR-Cas13a/C2c2. *Science* 356, 438541 442 (2017).
- 542 14. Chen, J. S. *et al.* CRISPR-Cas12a target binding unleashes indiscriminate single-stranded
- 543 DNase activity. *Science* **360**, 436-439 (2018).
- 15. East-Seletsky, A., O'Connell, M. R., Burstein, D., Knott, G. J. & Doudna, J. A. RNA
- targeting by functionally orthogonal type VI-A CRISPR-Cas enzymes. *Mol. Cell* 66, 373-383. e3
 (2017).
- 547 16. Ramachandran, A. & Santiago, J. G. CRISPR Enzyme Kinetics for Molecular Diagnostics.
 548 *Anal. Chem.* (2021).

- 549 17. Kellner, M. J., Koob, J. G., Gootenberg, J. S., Abudayyeh, O. O. & Zhang, F. SHERLOCK:
- nucleic acid detection with CRISPR nucleases. *Nature protocols* **14**, 2986-3012 (2019).
- 18. Sedlak, R. H. & Jerome, K. R. Viral diagnostics in the era of digital polymerase chain
- reaction. Diagn. Microbiol. Infect. Dis. 75, 1-4 (2013).
- 553 19. Hindson, C. M. et al. Absolute quantification by droplet digital PCR versus analog real-time
- 554 PCR. *Nature methods* **10**, 1003-1005 (2013).
- 555 20. Salipante, S. J. & Jerome, K. R. Digital PCR—an emerging technology with broad
- applications in microbiology. *Clin. Chem.* **66**, 117-123 (2020).
- 557 21. Lin, X., Huang, X., Urmann, K., Xie, X. & Hoffmann, M. R. Digital loop-mediated
- isothermal amplification on a commercial membrane. *ACS sensors* **4**, 242-249 (2019).
- 559 22. Abd El Wahed, A. *et al.* A portable reverse transcription recombinase polymerase
- amplification assay for rapid detection of foot-and-mouth disease virus. *PloS one* 8, e71642
 (2013).
- 562 23. Ooi, K. H. *et al.* An engineered CRISPR-Cas12a variant and DNA-RNA hybrid guides
- enable robust and rapid COVID-19 testing. *Nature communications* **12**, 1-23 (2021).
- 24. Park, J. S. *et al.* Digital CRISPR/Cas-Assisted Assay for Rapid and Sensitive Detection of
 SARS-CoV-2. *Advanced Science* 8, 2003564 (2021).
- 566 25. Yue, H. *et al.* Droplet Cas12a Assay Enables DNA Quantification from Unamplified
- 567 Samples at the Single-Molecule Level. *Nano Letters* (2021).

- 568 26. Tian, T. et al. An Ultralocalized Cas13a Assay Enables Universal and Nucleic Acid
- 569 Amplification-Free Single-Molecule RNA Diagnostics. ACS Nano (2020).
- 570 27. Wu, X. *et al.* Digital CRISPR-based method for the rapid detection and absolute
- quantification of nucleic acids. *Biomaterials*, 120876 (2021).
- 572 28. Woodman, C. B., Collins, S. I. & Young, L. S. The natural history of cervical HPV infection:
- unresolved issues. *Nature Reviews Cancer* 7, 11-22 (2007).
- 574 29. Piepenburg, O., Williams, C. H., Stemple, D. L. & Armes, N. A. DNA detection using
- recombination proteins. *PLoS Biol* **4**, e204 (2006).
- 576 30. Zhao, Y., Chen, F., Li, Q., Wang, L. & Fan, C. Isothermal amplification of nucleic acids.
- 577 *Chem. Rev.* **115**, 12491-12545 (2015).
- 578 31. Yeh, E. et al. Self-powered integrated microfluidic point-of-care low-cost enabling
- 579 (SIMPLE) chip. *Science advances* **3**, e1501645 (2017).
- 580 32. Li, J., Macdonald, J. & von Stetten, F. a comprehensive summary of a decade development
- of the recombinase polymerase amplification. *Analyst* **144**, 31-67 (2018).
- 582 33. Cohen, L. *et al.* Single molecule protein detection with attomolar sensitivity using droplet
- digital enzyme-linked immunosorbent assay. ACS nano 14, 9491-9501 (2020).
- 584 34. Wu, C., Garden, P. M. & Walt, D. R. Ultrasensitive detection of attomolar protein
- concentrations by dropcast single molecule assays. J. Am. Chem. Soc. 142, 12314-12323 (2020).

- 586 35. Gootenberg, J. S. *et al.* Multiplexed and portable nucleic acid detection platform with Cas13,
- 587 Cas12a, and Csm6. *Science* **360**, 439-444 (2018).
- 588 36. Trypsteen, W. et al. ddpcRquant: threshold determination for single channel droplet digital
- 589 PCR experiments. Analytical and bioanalytical chemistry **407**, 5827-5834 (2015).
- 590 37. Kaminski, M. M., Abudayyeh, O. O., Gootenberg, J. S., Zhang, F. & Collins, J. J. CRISPR-
- based diagnostics. *Nature Biomedical Engineering* **5**, 643-656 (2021).
- 592 38. Lillis, L. *et al.* Factors influencing Recombinase polymerase amplification (RPA) assay
- 593 outcomes at point of care. *Mol. Cell. Probes* **30**, 74-78 (2016).
- 39. Baret, J. Surfactants in droplet-based microfluidics. *Lab on a Chip* **12**, 422-433 (2012).
- 40. Gines, G. *et al.* Isothermal digital detection of microRNAs using background-free molecular
 circuit. *Science advances* 6, eaay5952 (2020).
- 597 41. Kalsi, S. *et al.* Rapid and sensitive detection of antibiotic resistance on a programmable
- digital microfluidic platform. *Lab on a Chip* **15**, 3065-3075 (2015).
- 42. Ellis, R. J. Macromolecular crowding: obvious but underappreciated. *Trends Biochem. Sci.*26, 597-604 (2001).

601